Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease

Chronic Kidney Diseases Clinical Trial

Official title:

Curcumin Supplementation for Improving Vascular and Cognitive Function in Chronic Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03223883
• Other study ID #: 201710769
• Status: Completed
• Phase: Phase 2
• Start date: January 30, 2018
• Est. completion date: January 25, 2023

Study information

• Verified date: May 2024
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed research is clinical study evaluating the therapeutic benefits of curcumin on vascular function in patients with chronic kidney disease (CKD). The study aims to establish that curcumin will improve endothelial function and reduce large artery stiffness by reducing oxidative stress and in conjunction with lowering markers of inflammation and oxidative stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive function in patients with CKD.

Description:

Patients with chronic kidney disease (CKD) are at increased risk of death from cardiovascular disease (CVD). Inflammation, oxidative stress and vascular dysfunction (impaired endothelial function and increased large elastic artery stiffness), are highly prevalent in CKD and contribute to the high incidence of CVD in this patient population. In addition, patients with CKD suffer from high rates of cognitive decline for which we lack effective therapies. Thus, therapeutic interventions targeting inflammation, oxidative stress, vascular dysfunction, and cognitive impairment in CKD are a biomedical priority. Curcumin is a natural polyphenol with anti-inflammatory and antioxidant characteristics. It is safe and widely-available. Preliminary data in old mice and healthy middle-aged (MA)/older adult humans indicate that curcumin administration improves endothelial dysfunction and large artery stiffness by reducing oxidative stress and inflammation. Additionally, 12 weeks of curcumin supplementation improves episodic memory in MA/older adults. The primary goal of this R01 application is to extend previous findings in healthy MA/older adults to patients with CKD, a growing clinical population with extensive baseline vascular dysfunction and cognitive impairment who presently have few treatment options. The hypothesis is that curcumin improves vascular endothelial function and large elastic artery stiffness in MA/older adults with stage IIIb and IV CKD (estimated GFR 15-45 mL/min/1.73m2). The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients. Specific aim 1a will determine if 12 months of curcumin supplementation will improve brachial artery-flow mediated dilation (BA-FMD) (endothelial function) and aortic pulse wave velocity (aPWV) (arterial stiffness) compared to placebo (randomized placebo-controlled double-blind study). Specific aim 1b will evaluate whether the curcumin-induced improvements in BA-FMD and aPWV are mediated by reduced oxidative stress, and will evaluate the effects of curcumin on systemic and endothelial cell markers of inflammation and oxidative stress. Importantly, specific aim 2 will evaluate the effects of curcumin supplementation on cognitive function, an important complication of CKD, using the NIH Cognitive Toolbox Battery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: January 25, 2023
• Est. primary completion date: January 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 74 Years

Eligibility

Inclusion Criteria:

• CKD stage IIIB and IV
• BMI<35 kg/m2
• Able to give informed consent

Exclusion Criteria:

• Consuming a diet rich in curcumin or taking curcumin supplements in the past 12 months
• Life expectancy <1 year
• Pregnant, breastfeeding, or unwilling to use adequate birth control
• Uncontrolled hypertension
• Severe liver disease
• Severe congestive heart failure
• Hospitalization within the last 3 months
• Active infection or antibiotic therapy
• Immunosuppressive therapy within the last year

Related Conditions & MeSH terms

• Chronic Kidney Diseases
• Cognitive Decline
• Cognitive Dysfunction
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Curcumin
Oral supplement for 12 months

Other:
• Placebo
Oral placebo for 12 months

Locations

Country	Name	City	State
United States	University of Iowa	Iowa City	Iowa

Sponsors (4)

Lead Sponsor	Collaborator
Diana Jalal	Stanford University, University of Colorado, Boulder, University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vascular endothelial function	Brachial artery flow-mediated dilation	12 months
Secondary	Large artery stiffness	Aortic pulse wave velocity	12 months
Secondary	Cognitive function	NIH toolbox battery	12 months